STAT April 3, 2024
Dana P. Goldman, Alison Sexton Ward

The latest weight loss drugs are good. Really good. They can save lives and could literally remake American health. But rather than celebrate, we’re having a political conversation that is all about price controls. Oscar Wilde’s warning is timely: Beware the fool who knows the price of everything and the value of nothing.

We and several of our colleagues have studied the new weight loss drugs, known as GLP-1s, like Wegovy (semaglutide) and Zepbound (tirzepatide), and modeled their impact. They represent huge value in treating obesity. More than 40% of adults in the U.S. have obesity; another one-third are overweight. An estimated 300,000 Americans die from obesity-related conditions each year.

Individuals with obesity participating in a clinical trial of Wegovy...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma / Biotech, Provider
109 hospitals receiving new Medicare-backed residency slots
Senators urge Congress to avert Medicare physician pay cut
Podcast: Medicare Shared Savings Program Mints $2B Win for Value-Based Care w/ Frank McStay
Medicare Part D in 2025: A First Look at Prescription Drug Plan Availability, Premiums, and Cost Sharing
Dr. Oz, RFK Jr. on Medicare, Medicaid: 10 notes

Share This Article